UNSPSC 51111757: Teloxantrone

This classification denotes an anthrapyrazole antibiotic with the molecular formula C21H25N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96521WL61B, chemically known as anthra(1,9-cd)pyrazol-6(2h)-one, 7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)- but generally known as teloxantrone, which bears US NIH Compound Identifier 5364123. European Medicines Agency schedules Teloxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10875MIG.

UNSPSC 51111757 Teloxantrone, a Commodity code, shows little relevant recent activity under its nominal scope. The two most recent state and local opportunities tagged to this code do not involve teloxantrone procurement; instead, they track pharmaceutical warehouse orders and emergency response medical supplies (naloxone and drug deactivation systems) that fall outside the teloxantrone product line. The mismatch between the code's narrow specificity and the actual goods being solicited suggests either misclassification in the source records or use of a catch-all pharmaceutical commodity code by issuing bodies without precision tagging.

The Illinois Department of Public Health awarded a piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for doxycycline and ciprofloxacin tablets totaling $2,999,999.11 over three years under an IFB process. Seminole County, Florida released an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2026 response deadline. Both procurements reflect state and local investment in pharmaceutical supply chains and emergency response capabilities, but neither represents teloxantrone buying. Without dedicated teloxantrone solicitations visible in recent state and local postings, this code does not present a clear market signal for business development purposes.